Rhombus Pharma
Rhombus Pharma is a Private Indian company incorporated in 1995 and based in Gujarat, India. Rhombus Pharma operates in Food & Beverages (NIC 15400) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.
Rhombus Pharma - Provider of veterinary care services for small animals.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Rhombus Pharma.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +30d | filed |
| MGT-7 | FY2024-25 | 23 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 27 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 25 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Rhombus Pharma.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 303431565 | Axis Bank Ltd(Bank) | ₹10.72 Cr | 12 Mar 2023 | Open |
| 879731110 | Axis Bank Ltd(Bank) | ₹11.73 Cr | 27 Jan 2021 | Open |
| 708092507 | State Bank of India(Bank) | ₹3.11 Cr | 19 Sep 2022 | Open |
| 607428088 | HDFC Bank Ltd(Bank) | ₹66.99 L | 19 Sep 2023 | Satisfied |
| 199856333 | Kotak Mahindra Bank Ltd(Bank) | ₹24.48 Cr | 12 Mar 2022 | Open |
Charge IDs, lenders & amounts for Rhombus Pharma.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
Locked| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| FY2024-25 | ₹7.47 Cr | ₹18.61 L | ₹3.57 Cr | ₹8.60 Cr | 145 |
| FY2023-24 | ₹6.07 Cr | ₹9.46 L | ₹4.44 Cr | ₹7.00 Cr | 88 |
| FY2022-23 | ₹5.85 Cr | ₹8.60 L | ₹3.30 Cr | ₹8.46 Cr | 281 |
| FY2021-22 | ₹3.55 Cr | ₹9.00 L | ₹2.31 Cr | ₹4.17 Cr | 57 |
Audited financials & ratios for Rhombus Pharma.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Detailed Financials
Locked| Line item | FY2024-25 | FY2023-24 | FY2022-23 | FY2021-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ₹7.47 Cr | ₹6.07 Cr | ₹5.85 Cr | ₹3.55 Cr |
| Other income | ₹25.22 L | ₹19.05 L | ₹21.62 L | ₹5.25 L |
| Total income | ₹7.72 Cr | ₹6.26 Cr | ₹6.07 Cr | ₹3.60 Cr |
| Total expenses | ₹7.48 Cr | ₹6.13 Cr | ₹5.96 Cr | ₹3.48 Cr |
| Profit before tax | ₹24.20 L | ₹12.30 L | ₹11.17 L | ₹11.70 L |
| Profit / (Loss) after tax | ₹18.61 L | ₹9.46 L | ₹8.60 L | ₹9.00 L |
| Balance sheet | ||||
| Equity / Net worth | ₹3.57 Cr | ₹4.44 Cr | ₹3.30 Cr | ₹2.31 Cr |
| Borrowings | ₹1.14 Cr | ₹97.15 L | ₹1.33 Cr | ₹38.59 L |
| Current liabilities | ₹2.16 Cr | ₹1.31 Cr | ₹1.67 Cr | ₹84.76 L |
| Total liabilities | ₹5.03 Cr | ₹2.56 Cr | ₹5.16 Cr | ₹1.86 Cr |
| Current assets | ₹4.10 Cr | ₹2.69 Cr | ₹3.96 Cr | ₹1.77 Cr |
| Cash & equivalents | ₹93.94 L | ₹88.96 L | ₹1.32 Cr | ₹50.99 L |
| Total assets | ₹8.60 Cr | ₹7.00 Cr | ₹8.46 Cr | ₹4.17 Cr |
| Employees | 145 | 88 | 281 | 57 |
Audited financials & ratios for Rhombus Pharma.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Compounded Annual Growth Rate
Locked| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue | ₹7.47 Cr | -7.3% | +4.7% | +11.1% |
| Profit after Tax | ₹18.61 L | +19.7% | +17.3% | +17.9% |
| Net Worth | ₹3.57 Cr | -0.6% | -4.5% | +16.8% |
| Employees | 145 | +20.8% | -6.0% | +2.4% |
Audited financials & ratios for Rhombus Pharma.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Financial Ratios
Locked| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| FY2024-25 | ₹7.47 Cr | ₹18.61 L | +2.49% | +21.94% | +5.21% | +2.16% | 0.32 | ₹5.15 L |
| FY2023-24 | ₹6.07 Cr | ₹9.46 L | +1.56% | +1.59% | +2.13% | +1.35% | 0.22 | ₹6.89 L |
| FY2022-23 | ₹5.85 Cr | ₹8.60 L | +1.47% | -0.67% | +2.60% | +1.02% | 0.40 | ₹2.08 L |
| FY2021-22 | ₹3.55 Cr | ₹9.00 L | +2.54% | +31.80% | +3.89% | +2.16% | 0.17 | ₹6.22 L |
Audited financials & ratios for Rhombus Pharma.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 3 | 4,02,54,079 | 82.30% |
| Institutional Investors | 1 | 20,29,086 | 4.15% |
| Public & Others | 55 | 66,26,465 | 13.55% |
Promoter, institutional & public holding for Rhombus Pharma.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
5 peersExternal data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.